Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
RXRXRecursion(RXRX) The Motley Fool·2024-07-27 17:41

There's a lot to like about the company using automation and artificial intelligence to improve the new drugdiscovery process. Recursion Pharmaceuticals (RXRX 3.73%) is a start-up biotech company with an important twist. It's using automation technology and artificial intelligence (AI) to industrialize new drug discovery. Why Recursion Pharmaceuticals looks like a good investment New drug candidates discovered by Recursion should also have a better chance at success in clinical trials because there's a lot ...